COEP News and Press, Coeptis Therapeutics Inc From 02/26/24

Coeptis Therapeutics Adds Autoimmune Indications to Exclusive License Agreement with University of Pittsburgh for SNAP-CAR T and SNAP-CAR NK PR Newswire Exclusive rights to universal CAR technology platform designed to target multiple antigens simultaneously, recently expanded...

Propanc Biopharma Inc (PPCB) is expected to report for Q2 2024 Bank of Georgia Group Plc (BDGSF) is expected to report for quarter end 2023-12-31 Arch Resources Inc. Class A (ARCH) is expected to report $6.9 for Q4 2023 Bloom Energy Corporation Class A (BE) is expected to report $-0.0...

Turnstone Biologics Corp. (TSBX) is expected to report $-0.73 for Q4 2023 Exro Technologies Inc (EXROF) is expected to report for Q4 2023 Boyd Gaming Corporation (BYD) is expected to report $1.43 for Q4 2023 Onto Innovation Inc. (ONTO) is expected to report $0.99 for Q4 2023 Motor...

Coeptis Therapeutics Holdings Inc. (COEP) is expected to report for Q4 2023

Coeptis Therapeutics to Pursue Phase 2 Program Using Proprietary First-in-Class Allogeneic NK Cell Therapy for the Treatment of Viral Infections PR Newswire Novel NK cell therapy approach is designed to bolster and replenish the immune system during severe viral infection...

Coeptis Therapeutics President and CEO Issues Letter to Shareholders Highlighting 2023 Accomplishments and Outlook for 2024 PR Newswire WEXFORD, Pa. , Jan. 4, 2024 /PRNewswire/ -- Coeptis Therapeutics Holdings, Inc. (NASDAQ: COEP) (the "Company" or "Coeptis"), a ...

Coeptis Therapeutics Announces Research Demonstrating the Potential of SNAP-CAR T-cells to Reduce Tumor Burden and Growth in HER2 and CD20 Expressing Cancers Will be Presented at SITC 2023 PR Newswire Poster presentation describes the development of SNAP CAR platform technolog...

2023-10-24 08:46:59 ET More on Coeptis Therapeutics Holdings, Inc. Seeking Alpha’s Quant Rating on Coeptis Therapeutics Holdings, Inc. Historical earnings data for Coeptis Therapeutics Holdings, Inc. Financial information for Coeptis Therapeutics Holdings, Inc...

Coeptis Therapeutics Announces $2 Million Private Placement PR Newswire WEXFORD, Pa. , Oct. 24, 2023 /PRNewswire/ -- Coeptis Therapeutics Holdings, Inc. (NASDAQ: COEP) ("Coeptis" or "the Company"), a biopharmaceutical company developing innovative cell therapy pl...

Coeptis Therapeutics Expands License Agreement with University of Pittsburgh to Include SNAP-CAR NK Cell Technology PR Newswire Coeptis now has exclusive rights to SNAP-CAR NK and SNAP-CAR T-Cell technology platforms WEXFORD, Pa. , Oct. 11, 2023 /PRNewswi...